Novuson Surgical, a spinout from the University of Washington's Applied Physics Center for Industrial and Medical Ultrasound, specializes in advanced energy technology for surgical and trauma procedures. The company has developed Direct Therapeutic Ultrasound (DTU) technology, a groundbreaking innovation in vessel sealing, dividing, and hemostasis (bleeding control). Novuson's products, such as the 3mm Mini LS and the 10mm UltraStat MAXX, are designed to improve surgical efficiency, reduce anesthesia time, and minimize the need for blood products, thereby enhancing patient outcomes and lowering healthcare costs. The company's primary clients include hospitals, surgical centers, and trauma units. Novuson operates in the medical device market, focusing on minimally invasive surgery and trauma care. The business model revolves around the sale of its proprietary medical devices, generating revenue through direct sales and potential licensing agreements.

Keywords: Direct Therapeutic Ultrasound, vessel sealing, hemostasis, surgical efficiency, trauma care, medical devices, minimally invasive surgery, healthcare cost reduction, patient outcomes, advanced energy technology.